Yahoo
NasdaqCM - Nasdaq Real Time Price USD

Moleculin Biotech, Inc. (MBRX)

8.72 -0.02 (-0.29%)
At close: October 29 at 4:00:01 PM EDT
Chart Range Bar
Loading chart for MBRX
Chart does not reflect overnight price.
  • Previous Close 8.74
  • Open 8.70
  • Bid 0.26 x 300
  • Ask 6.28 x 100
  • Day's Range 8.08 - 8.84
  • 52 Week Range 3.22 - 315.00
  • Volume 33,931
  • Avg. Volume 73,083
  • Market Cap (intraday) 8.888M
  • Beta (5Y Monthly) 2.00
  • PE Ratio (TTM) 0.05
  • EPS (TTM) 174.79
  • Earnings Date --
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 240.00
  • Zacks Rating Neutral

Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 portfolio, including WP1066, WP1193, and WP1220, which are immune/transcription modulators designed to inhibit phosphorylated signal transducer and activator of transcription for brain tumors and pancreatic and other cancers. In addition, it is developing WP1122 portfolio, such as WP1122, WP1096, and WP1097 designed to exploit the uses of inhibitors of glycolysis comprising 2-deoxy-D-glucose that cut off the energy supply of tumors. The company was incorporated in 2015 and is headquartered in Houston, Texas.

moleculin.com

17

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview

Trailing total returns as of 10/29/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

MBRX
163.44%
S&P 500 (^GSPC)
12.78%

1-Year Return

MBRX
27.33%
S&P 500 (^GSPC)
12.04%

3-Year Return

MBRX
95.16%
S&P 500 (^GSPC)
87.51%

5-Year Return

MBRX
99.12%
S&P 500 (^GSPC)
67.64%

Earnings Trends

View More

Earnings Per Share (GAAP)

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY26
Revenue --
Earnings -14.61M
Profit Margin 0.00%

Q2

FY25

Q3

FY25

Q4

FY25

Q1

FY26

-20M
-10M
0
10M
0.0%

Analyst Insights

View More

Analyst Price Targets

40.00
240.00 Average
8.72 Current
620.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 8/28/2026
Analyst HC Wainwright & Co.
Rating Action Maintains
Rating Buy
Price Action Lowers
Price Target 22 -> 3

Statistics

View More

Valuation Measures

Annual
As of 10/28/2026
  • Market Cap

    9.13M

  • Enterprise Value

    2.16M

  • Trailing P/E

    0.05

  • Forward P/E

    --

  • PEG Ratio (current)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    0.27

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -84.57%

  • Return on Equity (ttm)

    -1,371.64%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -32.52M

  • Diluted EPS (ttm)

    174.79

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    7.26M

  • Total Debt/Equity (mrq)

    2.52%

  • Levered Free Cash Flow (ttm)

    -14.92M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

8.72 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: